Weiss Ratings Reiterates “Sell (E+)” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report)‘s stock had its “sell (e+)” rating reiterated by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Galmed Pharmaceuticals currently has an average rating of “Reduce”.

Check Out Our Latest Research Report on Galmed Pharmaceuticals

Galmed Pharmaceuticals Stock Performance

Shares of Galmed Pharmaceuticals stock opened at $1.55 on Wednesday. The business’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $1.54. Galmed Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $4.81. The firm has a market cap of $2.56 million, a PE ratio of -0.09 and a beta of 0.50.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

Featured Articles

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.